Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same

Patent metadata

Field	Value
Publication number	US-9675675-B2
Application number	US-201214361802-A
Country	US
Kind code	B2
Filing date	Nov 30, 2012
Priority date	Nov 30, 2011
Publication date	Jun 13, 2017
Grant date	Jun 13, 2017

Abstract

A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid. A method of stabilizing a peptide therapeutic agent with an amino acid on an array of microneedles is also disclosed. In some cases, the peptide therapeutic agent and the amino acid either both have a net positive charge or both have a net negative charge. In some cases, the peptide therapeutic agent is histidine.

First claim

What is claimed is:

1. A medical device comprising:
an array of microneedles; and
a coating on or within at least a portion of the microneedles, wherein the coating comprises:
a peptide therapeutic agent; and
an amino acid,

wherein the coating is substantially free of sorbitol, and wherein one of the following is true:
the peptide therapeutic agent has a net positive charge at a pH in a range from 7 to 7.4, and the amino acid has a net positive charge at the pH; or
the peptide therapeutic agent has a net negative charge at a pH in a range from 7 to 7.4, and the amino acid has a net negative charge at the pH.

2. The medical device of claim 1 , wherein the amino acid is histidine, arginine, lysine, aspartic acid, or glutamic acid.

3. The medical device of claim 2 , wherein the amino acid is histidine.

4. The medical device of claim 1 , wherein the peptide therapeutic agent has a net positive charge at the pH, and the amino acid has a net positive charge at the pH.

5. A medical device comprising:
an array of microneedles; and
a coating on or within at least a portion of the microneedles, wherein the coating comprises:
a peptide therapeutic agent; and
histidine,

wherein the molar ratio of the histidine to the peptide therapeutic agent is less than 2.1.

6. The medical device of claim 5 , wherein the molar ratio of the histidine to the peptide therapeutic agent is less than 1.5:1.

7. The medical device of claim 5 , wherein the peptide therapeutic agent has a net positive charge.

8. The medical device of claim 5 , wherein the histidine stabilizes the peptide therapeutic agent in the coating.

9. The medical device of claim 1 , wherein the array of microneedles comprises a dissolvable matrix material or wherein at least a portion of the microneedles are hollow.

10. A method of making the medical device of claim 1 , the method comprising:
providing an aqueous composition comprising a peptide therapeutic agent, an amino acid, and a buffer, wherein the aqueous composition has a pH, wherein the peptide therapeutic agent has a net positive charge at the pH of the aqueous composition, and the amino acid has a net positive charge at the pH of the aqueous composition, or wherein the peptide therapeutic agent has a net negative charge at the pH of the aqueous composition, and the amino acid has a net negative charge at the pH of the aqueous composition;
contacting the microneedles with the aqueous composition; and
volatilizing a portion of the aqueous composition to provide a coating on at least a portion of the microneedles, wherein the coating comprises at least the peptide therapeutic agent and the amino acid.

11. The method of claim 10 , wherein the pH of the aqueous composition is in a range from 3 to 11.

12. The method of claim 10 , wherein the amino acid stabilizes the peptide therapeutic agent on or within an array of the microneedles.

13. The method of claim 10 , wherein the amino acid is histidine, arginine, lysine, aspartic acid, or glutamic acid.

14. The method of claim 10 , wherein the peptide therapeutic agent has a net positive charge at the pH of the aqueous composition, and the amino acid has a net positive charge at the pH of the aqueous composition.

15. A method of making the medical device of claim 5 , the method comprising:
providing an aqueous composition comprising the peptide therapeutic agent, histidine, and a buffer, wherein the molar ratio of the histidine to the peptide therapeutic agent in the aqueous composition is less than 2:1;
contacting the microneedles with the aqueous composition; and
volatilizing a portion of the aqueous composition to provide a coating on at least a portion of the microneedles, wherein the coating comprises at least the peptide therapeutic agent and the histidine.

16. The method of claim 10 , wherein the buffer comprises phosphate, acetate, citrate, or tris(hydroxymethyl)aminomethane.

17. The medical device of claim 5 , wherein the peptide therapeutic agent is parathryroid hormone, calcitonin, lysozyme, insulin, glatiramer acetate, goserelin acetate, octreotide, leuprolide, vasopressin, atrial natriuretic peptide (ANP), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), erythropoietin (EPO), bone morphogenetic proteins (BMPs), epidermal growth factor (EFG), granulocyte clony-stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), interferon alpha, interferon beta, interferon gamma, antimicrobial peptides, dornase alfa, tissue plasminogen activator, a fusion protein, or a vaccine.

18. The medical device of claim 1 , wherein the molar ratio of the amino acid to the peptide therapeutic agent is less than 2:1.

19. The medical device of claim 1 , wherein the molar ratio of the amino acid to the peptide therapeutic agent is in a range from 0.5:1 to 55:1.

20. The medical device of claim 1 , wherein the peptide therapeutic agent is parathryroid hormone, calcitonin, lysozyme, insulin, glatiramer acetate, goserelin acetate, octreotide, leuprolide, vasopressin, atrial natriuretic peptide (ANP), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), erythropoietin (EPO), bone morphogenetic proteins (BMPs), epidermal growth factor (EFG), granulocyte clony-stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), interferon alpha, interferon beta, interferon gamma, antimicrobial peptides, dornase alfa, tissue plasminogen activator, a fusion protein, or a vaccine.

Assignees

• 3M Innovative Properties Co

Inventors

• Zhang Ying
• Fenn Percy T
• Johnson Peter R

Classifications

• A61K31/198

  Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) · CPC title

• A61K38/47

  acting on glycosyl compounds (3.2), e.g. cellulases, lactases · CPC title

• A61K31/4172

  Imidazole-alkanecarboxylic acids, e.g. histidine · CPC title

• A61M2037/0023

  Drug applicators using microneedles · CPC title

• A61L31/10

  Macromolecular materials · CPC title